A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Paricalcitol
Azilsartan medoxomil
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Aminophenazone.
Paricalcitol
Saralasin
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Aminophenazone.
Paricalcitol
Tasosartan
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Aminophenazone.
Paricalcitol
Saprisartan
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Aminophenazone.
Paricalcitol
Forasartan
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Aminophenazone.
Paricalcitol
Irbesartan
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Aminophenazone.
Paricalcitol
Cyproterone acetate
The metabolism of Aminophenazone can be increased when combined with Cyproterone acetate.
Paricalcitol
Edetic acid
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Edetic acid.
Paricalcitol
Troxerutin
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Troxerutin.
Paricalcitol
Reviparin
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Reviparin.
Paricalcitol
Dabigatran
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Dabigatran.
Paricalcitol
Edetate calcium disodium anhydrous
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Edetate calcium disodium anhydrous.
Paricalcitol
Tocopherylquinone
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Tocopherylquinone.
Paricalcitol
(S)-Warfarin
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with (S)-Warfarin.
Paricalcitol
Saruplase
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Saruplase.
Paricalcitol
Melagatran
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Melagatran.
Paricalcitol
Tioclomarol
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Tioclomarol.
Paricalcitol
Diphenadione
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Diphenadione.
Paricalcitol
Clorindione
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Clorindione.
Paricalcitol
Brinase
The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Brinase.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3